Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
NCT ID: NCT00003901
Last Updated: 2017-02-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1310 participants
INTERVENTIONAL
1999-07-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer
NCT00003006
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
NCT03710616
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
NCT06842056
Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01517971
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
NCT02380196
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the relationship between three indicators of occult metastases (cytological examination of pleural lavage, immunohistochemistry (IHC) assay of lymph nodes, and IHC assay of rib bone marrow) and survival of patients with resectable non-small cell lung cancer.
* Determine the relationship between these indicators and conventional histology.
* Model survival considering the indicators and other patient attributes that are of prime prognostic significance.
* Determine the relationships between the indicators and the site of first recurrence in these patients.
* Determine the prevalence of the indicators in these patients.
* Determine the relationships between the indicators and disease free survival in these patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Surgery
All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.
Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.
Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years.
immunohistochemistry staining method
biopsy
surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immunohistochemistry staining method
biopsy
surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient must have ECOG/Zubrod status \< 3.
3. Patient must have clinically resectable, NSCLC (squamous cell, adenocarcinoma, or large cell) and be clinical Stage I, IIa, IIb or IIIa, according to the 1998 staging system of the American Joint Commission on Cancer for lung cancer.
4. Patient must have N1 or N2 disease. NOTE: Patient must undergo mediastinoscopy if preoperative studies suggest N3 disease.
5. Patient must have a pathologic diagnosis (pre-operative or intra-operative) of NSCLC prior to registration.
6. Patient must be anticipated to have a thoracotomy with the intention of a curative resection for primary NSCLC. NOTE: The preoperative assessment of resectability should, at a minimum, include a CT scan of the chest and upper abdomen, including the adrenal glands, within 60 days prior to registration.
7. Patient must be medically fit for surgery.
8. Patient must be a candidate for complete resection of the carcinoma via pneumonectomy, bilobectomy, lobectomy, or anatomic segmentectomy with or without sleeve resection.
9. Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures.
10. Patient must be available for follow-up.
11. If the patient is a survivor of a prior cancer, all of the following criteria must apply:
1. Patient has undergone potentially curative therapy for all prior malignancies,
2. No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone),
3. Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.
Exclusion Criteria
2. Patient has had ipsilateral thoracotomy or thoracoscopy within the past 5 years.
3. Patient has received prior chemotherapy or radiotherapy for this cancer.
4. Patient is considered a poor surgical risk due to non-malignant systemic disease (cardiovascular, renal, etc.) that would preclude the treatment options.
5. Patient for whom the surgeon plans to perform only a wedge resection for treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Alliance for Clinical Trials in Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robbin G. Cohen, MD
Role: STUDY_CHAIR
University of Southern California
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Cancer Center
Mobile, Alabama, United States
Mobile Infirmary Medical Center
Mobile, Alabama, United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
Huntington Cancer Center at Huntington Hospital
Pasadena, California, United States
University of California Davis Cancer Center
Sacramento, California, United States
UCSF Comprehensive Cancer Center
San Francisco, California, United States
University of Colorado Health Sciences Center - Denver
Denver, Colorado, United States
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, United States
Bayfront Medical Center
St. Petersburg, Florida, United States
University of Chicago Cancer Research Center
Chicago, Illinois, United States
Alexian Brothers Medical Center
Elk Grove Village, Illinois, United States
Cancer Institute at St. John's Hospital
Springfield, Illinois, United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States
Jewish Hospital
Louisville, Kentucky, United States
McLaren Regional Cancer Center
Flint, Michigan, United States
Hurley Medical Center
Flint, Michigan, United States
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan, United States
Siteman Cancer Center
St Louis, Missouri, United States
Veterans Affairs Medical Center - Omaha
Omaha, Nebraska, United States
Creighton University School of Medicine
Omaha, Nebraska, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, United States
Long Island Cancer Center at Stony Brook University Hospital
Stony Brook, New York, United States
University Hospital at State University of New York - Upstate Medical University
Syracuse, New York, United States
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, United States
Ireland Cancer Center
Cleveland, Ohio, United States
MetroHealth's Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, United States
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, United States
Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States
Westmoreland Regional Hospital
Greensburg, Pennsylvania, United States
Jameson Memorial Hospital
New Castle, Pennsylvania, United States
Abramson Cancer Center of the University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
St. Clair Memorial Hospital
Pittsburgh, Pennsylvania, United States
Lankenau Cancer Center at Lankenau Hospital
Wynnewood, Pennsylvania, United States
Saint Thomas Hospital
Nashville, Tennessee, United States
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
Nashville, Tennessee, United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Cottonwood Hospital Medical Center
Murray, Utah, United States
LDS Hospital
Salt Lake City, Utah, United States
Cancer Center at the University of Virginia
Charlottesville, Virginia, United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, United States
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, United States
University Cancer Center at University of Washington Medical Center
Seattle, Washington, United States
West Virginia University Hospitals
Morgantown, West Virginia, United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, United States
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, Patterson GA, Inculet RI, Jones DR, Malthaner RA, Cohen RG, Ballman K, Putnam JB Jr, Cote RJ. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011 Nov 10;29(32):4313-9. doi: 10.1200/JCO.2011.35.2500. Epub 2011 Oct 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000067072
Identifier Type: REGISTRY
Identifier Source: secondary_id
ACOSOG-Z0040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.